Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 8 | 9 |
| 2003 | 1 | 5 | 6 |
| 2004 | 2 | 9 | 11 |
| 2005 | 2 | 5 | 7 |
| 2006 | 3 | 2 | 5 |
| 2007 | 5 | 8 | 13 |
| 2008 | 7 | 9 | 16 |
| 2009 | 5 | 4 | 9 |
| 2010 | 8 | 18 | 26 |
| 2011 | 3 | 11 | 14 |
| 2012 | 9 | 16 | 25 |
| 2013 | 10 | 13 | 23 |
| 2014 | 11 | 18 | 29 |
| 2015 | 7 | 17 | 24 |
| 2016 | 16 | 12 | 28 |
| 2017 | 13 | 20 | 33 |
| 2018 | 22 | 12 | 34 |
| 2019 | 14 | 21 | 35 |
| 2020 | 14 | 16 | 30 |
| 2021 | 11 | 11 | 22 |
| 2022 | 2 | 7 | 9 |
| 2023 | 5 | 5 | 10 |
| 2024 | 10 | 7 | 17 |
| 2025 | 8 | 5 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents. Leuk Lymphoma. 2025 Dec; 66(13):2437-2447.
-
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin. Blood. 2025 Jul 24; 146(4):471-481.
-
Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochim Biophys Acta Rev Cancer. 2025 Oct; 1880(5):189396.
-
PARP-1 as a novel target in endocrine-resistant breast cancer. J Exp Clin Cancer Res. 2025 Jun 16; 44(1):175.
-
Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors. Clin Chem. 2025 Jun 03; 71(6):700-712.
-
3D genome organization shapes DNA damage susceptibility to platinum-based drugs. Nucleic Acids Res. 2025 May 22; 53(10).
-
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
-
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients. Eur J Haematol. 2025 Jul; 115(1):16-28.
-
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May; 39(5):1058-1068.
-
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194.